EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
    1.3.1.9 | Breast Neoplasms |
11935210 |
Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells. |
causal interaction
ongoing research
therapeutic application
unassigned |
4
4
4
0 |
| 1.3.1.9 | Infections |
24277048 |
The Burkholderia pseudomallei enoyl-acyl carrier protein reductase FabI1 is essential for in vivo growth and is the target of a novel chemotherapeutic with efficacy. |
causal interaction
therapeutic application
unassigned |
3
4
0 |
| 1.3.1.9 | Infections |
25517015 |
Design, synthesis, and evaluation of new thiadiazole-based direct inhibitors of enoyl acyl carrier protein reductase (InhA) for the treatment of tuberculosis. |
therapeutic application
unassigned |
4
0 |
| 1.3.1.9 | Lung Neoplasms |
29151986 |
Pyrrolyl Pyrazoline Carbaldehydes as Enoyl-ACP Reductase Inhibitors: Design, Synthesis and Antitubercular Activity. |
ongoing research
therapeutic application
unassigned |
4
2
0 |
| 1.3.1.9 | Malaria |
22969045 |
Dynamics of Plasmodium falciparum enoyl-ACP reductase and implications on drug discovery. |
therapeutic application
unassigned |
1
0 |
| 1.3.1.9 | Toxoplasmosis |
23776166 |
Modification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in Toxoplasma gondii. |
therapeutic application
unassigned |
4
0 |
| 1.3.1.9 | Tuberculosis |
9728546 |
Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. |
ongoing research
therapeutic application
unassigned |
2
1
0 |
| 1.3.1.9 | Tuberculosis |
10869086 |
Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. |
therapeutic application
unassigned |
3
0 |
| 1.3.1.9 | Tuberculosis |
12606558 |
Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data. |
causal interaction
therapeutic application
unassigned |
2
4
0 |
| 1.3.1.9 | Tuberculosis |
14740053 |
An inorganic iron complex that inhibits wild-type and an isoniazid-resistant mutant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis. |
ongoing research
therapeutic application
unassigned |
2
1
0 |
